JP2023519246A5 - - Google Patents
Info
- Publication number
- JP2023519246A5 JP2023519246A5 JP2022557767A JP2022557767A JP2023519246A5 JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5 JP 2022557767 A JP2022557767 A JP 2022557767A JP 2022557767 A JP2022557767 A JP 2022557767A JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai drug
- rnai
- sense strand
- drug according
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025168554A JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000137P | 2020-03-26 | 2020-03-26 | |
| US63/000,137 | 2020-03-26 | ||
| PCT/US2021/024299 WO2021195467A2 (en) | 2020-03-26 | 2021-03-26 | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025168554A Division JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519246A JP2023519246A (ja) | 2023-05-10 |
| JP2023519246A5 true JP2023519246A5 (cg-RX-API-DMAC7.html) | 2024-04-03 |
| JP7830340B2 JP7830340B2 (ja) | 2026-03-16 |
Family
ID=75540055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557767A Active JP7830340B2 (ja) | 2020-03-26 | 2021-03-26 | PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 |
| JP2025168554A Pending JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025168554A Pending JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法 |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2022256395A1 (en) * | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| CN119789859A (zh) * | 2022-04-08 | 2025-04-08 | 箭头药业股份有限公司 | 非酒精性脂肪肝病的治疗 |
| WO2025223315A1 (zh) * | 2024-04-25 | 2025-10-30 | 苏州时安生物技术有限公司 | 一种用于肝脏特异性递送的多靶标双链rna偶联物及药物组合物 |
| WO2026130520A1 (zh) * | 2024-12-20 | 2026-06-25 | 正大天晴药业集团股份有限公司 | 靶向pnpla3的双链核糖核酸 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法 |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| CN115176007A (zh) * | 2019-12-16 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | 含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法 |
-
2021
- 2021-03-26 KR KR1020227036413A patent/KR20220158011A/ko active Pending
- 2021-03-26 JP JP2022557767A patent/JP7830340B2/ja active Active
- 2021-03-26 BR BR112022019241A patent/BR112022019241A2/pt unknown
- 2021-03-26 CN CN202510877568.XA patent/CN120699970A/zh active Pending
- 2021-03-26 EP EP21719475.2A patent/EP4125932A2/en active Pending
- 2021-03-26 WO PCT/US2021/024299 patent/WO2021195467A2/en not_active Ceased
- 2021-03-26 CN CN202180024737.5A patent/CN115397436B/zh active Active
- 2021-03-26 UY UY0001039138A patent/UY39138A/es unknown
- 2021-03-26 TW TW110111184A patent/TWI924663B/zh active
- 2021-03-26 MX MX2022011907A patent/MX2022011907A/es unknown
- 2021-03-26 US US17/213,787 patent/US12054718B2/en active Active
- 2021-03-26 IL IL296718A patent/IL296718A/en unknown
- 2021-03-26 AR ARP210100762A patent/AR121672A1/es unknown
- 2021-03-26 AU AU2021242321A patent/AU2021242321B2/en active Active
- 2021-03-26 PE PE2022002098A patent/PE20230345A1/es unknown
- 2021-03-26 CR CR20220532A patent/CR20220532A/es unknown
- 2021-03-26 CA CA3176418A patent/CA3176418A1/en active Pending
-
2022
- 2022-09-23 DO DO2022000204A patent/DOP2022000204A/es unknown
- 2022-09-23 CL CL2022002580A patent/CL2022002580A1/es unknown
- 2022-09-25 JO JOJO/P/2022/0232A patent/JOP20220232A1/ar unknown
- 2022-09-26 CO CONC2022/0013746A patent/CO2022013746A2/es unknown
- 2022-09-26 EC ECSENADI202275322A patent/ECSP22075322A/es unknown
-
2023
- 2023-08-31 CL CL2023002586A patent/CL2023002586A1/es unknown
-
2024
- 2024-06-20 US US18/748,261 patent/US20250034577A1/en active Pending
-
2025
- 2025-10-06 JP JP2025168554A patent/JP2026010008A/ja active Pending
- 2025-11-11 AU AU2025267339A patent/AU2025267339A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533334A5 (cg-RX-API-DMAC7.html) | ||
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| JP2022501040A5 (cg-RX-API-DMAC7.html) | ||
| JP6924744B2 (ja) | B型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| TWI881004B (zh) | 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合 | |
| JP2023536974A5 (cg-RX-API-DMAC7.html) | ||
| KR20200097751A (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| JP2020534268A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529732A5 (cg-RX-API-DMAC7.html) | ||
| JP2019513384A5 (cg-RX-API-DMAC7.html) | ||
| JP2023536999A (ja) | B型肝炎患者のオリゴヌクレオチド処置 | |
| US20240425859A1 (en) | Pharmaceutical combinations for treatment of hbv | |
| JP2024539193A5 (cg-RX-API-DMAC7.html) | ||
| JP2022517742A5 (cg-RX-API-DMAC7.html) | ||
| JP2024544532A5 (cg-RX-API-DMAC7.html) | ||
| IL323704A (en) | Compounds and methods for reducing pln expression | |
| US20230123601A1 (en) | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv | |
| JP2023541170A (ja) | Z-aatタンパク質のレベルを低下させる方法 | |
| JP2024026903A (ja) | siRNA及び医薬組成物並びに予防及び/又は治療剤 | |
| WO2021107143A1 (ja) | アンチセンス核酸の毒性を軽減する方法 | |
| HK40110728A (en) | Pharmaceutical combinations for treatment of hbv | |
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 | |
| CN120829899A (zh) | 用于抑制NR1H3基因表达的RNAi剂及其制备方法和用途 | |
| CN117645995A (zh) | 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途 | |
| TH2001001206A (th) | RNAi เอเจนท์และองค์ประกอบสำหรับการยับยั้งการแสดงออกของอะโปลิโพโปรตีน C-II (APOC3) |